TITLE:

EMA: CHMP adopted a positive opinion for Ocrevus (ocrelizumab) 300-mg concentrate for solution for infusion from Roche Registration Limited.

BRIEF:

EMA: CHMP adopted a positive opinion for Ocrevus (ocrelizumab) 300-mg concentrate for solution for infusion from Roche Registration Limited. Ocrevus is intended for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.(ATC code: L04AA36). The EC Decision will follow soon.